Cargando…
Polymyxin B combinations with FDA-approved non-antibiotic phenothiazine drugs targeting multi-drug resistance of Gram-negative pathogens
The status quo for combating uprising antibacterial resistance is to employ synergistic combinations of antibiotics. Nevertheless, the currently available combination therapies are fast becoming untenable. Combining antibiotics with various FDA-approved non-antibiotic drugs has emerged as a novel st...
Autores principales: | Hussein, Maytham, Hu, Xiaohan, Paulin, Olivia K.A., Crawford, Simon, Tony Zhou, Qi, Baker, Mark, Schneider-Futschik, Elena K., Zhu, Yan, Li, Jian, Velkov, Tony |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Research Network of Computational and Structural Biotechnology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481501/ https://www.ncbi.nlm.nih.gov/pubmed/32952938 http://dx.doi.org/10.1016/j.csbj.2020.08.008 |
Ejemplares similares
-
Drug Repurposing Approaches towards Defeating Multidrug-Resistant Gram-Negative Pathogens: Novel Polymyxin/Non-Antibiotic Combinations
por: Koh Jing Jie, Augustine, et al.
Publicado: (2022) -
Mechanistic Insights From Global Metabolomics Studies into Synergistic Bactericidal Effect of a Polymyxin B Combination With Tamoxifen Against Cystic Fibrosis MDR Pseudomonas aeruginosa
por: Hussein, Maytham, et al.
Publicado: (2018) -
Sputum Active Polymyxin Lipopeptides: Activity against
Cystic Fibrosis Pseudomonas aeruginosa Isolates and
Their Interactions with Sputum Biomolecules
por: Schneider-Futschik, Elena K., et al.
Publicado: (2018) -
Comparative Proteomics of Outer Membrane Vesicles from Polymyxin-Susceptible and Extremely Drug-Resistant Klebsiella pneumoniae
por: Hussein, Maytham, et al.
Publicado: (2023) -
The Killing Mechanism of Teixobactin against Methicillin-Resistant Staphylococcus aureus: an Untargeted Metabolomics Study
por: Hussein, Maytham, et al.
Publicado: (2020)